<DOC>
	<DOCNO>NCT00478374</DOCNO>
	<brief_summary>The purpose study determine feasibility combine sorafenib transarterial chemoembolisation patient suffer hepatocellular carcinoma.The hypothesis sorafenib may prevent development growth tumoral lesion treat chemoembolisation .</brief_summary>
	<brief_title>Sorafenib With TACE Treat Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients inoperable HCC , candidate transarterial chemoembolization ( TACE ) . Diagnosis hepatocellular carcinoma base EASL 's criterion ( 1 ) . ChildPugh score &lt; 10 ( Child A B ) , Life expectancy superior 12 week pretreatment evaluation . Local therapy interrupt least 4 week Written inform consent sign Age &gt; = 18 Performance status ECOG 01 Normal organ marrow function define : Haematopoietic : absolute neutrophil count &gt; 1,500/mm3 , platelet count &gt; 60,000/mm3 , haemoglobin &gt; 9g/dL INR &lt; 1.5 ULN PTT within normal limit Hepatic : AST ALT &lt; 5 x ULN Renal : creatinine &lt; 1.5 x ULN Women childbearing potential must negative serum pregnancy test perform within 7 day prior start treatment Women childbearing potential men must agree use adequate birth contraception ( must double method record ) prior study entry duration study participation . For men woman , adequate birth control measure must use least 3 month last administration study drug . Active heart disease define congestive heart failure &gt; NYHA ( New York Heart Association ) class 2 ; active coronary artery disease ( myocardial infarction 6 month prior study entry allow ) ; cardiac arrhythmia require antiarrhythmic therapy ( betablockers digoxin permit ) uncontrolled hypertension . Congestive heart failure , serious cardiac arrhythmia , active coronary artery disease . Thrombotic embolic event within past 6 month cerebrovascular accident ( include transient ischemic attack ) , pulmonary embolism . Uncontrolled intercurrent illness include , limited , ongoing active infection . Psychiatric illness/social situation would limit compliance study requirement . Patients evidence active infection become eligible reconsideration 7 day complete antibiotic therapy . HIVpositive patient receive combination antiretroviral therapy exclude study possible pharmacokinetic interaction sorafenib . Patients treat sorafenib . Cerebral metastasis . ChildPugh score C. Hypertension define systolic blood pressure great 150 mmHg diastolic pressure great 90 mmHg despite optimal medical management . Proteinuria define 24hour urine protein excretion great 1000 mg. Urine dipstick proteinuria 1+ great require 24hour urine determine eligibility enrolment . Therapeutic anticoagulation coumarin , heparin , heparinoids . Serious nonhealing wound ( include wound heal secondary intention ) , acute nonhealing ulcer , bone fracture within 3 month fracture . Evidence bleed diathesis . Impairment swallow would preclude administration sorafenib . History haemoptysis surgery within past 28 day . Organ allograft . Pregnant breastfeeding patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>